OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Good to see a 'buy' of 850,000 go through at 3.10pm. I wonder if Boris Jordon
is continuing to build up his stake?.

'The Independent Newspaper' on 7/2/05 had an interesting article on OXB and
mentioned that Boris Jordon has recently met up with the OXB Board for
discussions. I wonder what these discussions were about? The article
also mentions that the Board have been holding talks for several weeks with
a number of different parties.

Expect to see more 850,000 plus 'buys' over the next few weeks.

Morning All!

Pleased to read this morning that the 'Money Week'Magazine included a summary
of 'The Times' newspaper's 'buy'recommendation earlier this week. However,
would have been more pleased to if the 'Money Week' magazine had featured a
'buy' recommendation also.

Can anyone verify whether OXB has a working partnership with Cobra Bio? If
so this could be positive news ahead of the oxb results because Cobra Bio was
up over 30% this morning.

I'm off on annual leave again next week (tee hee hee!). Well it is pointless
me being at my desk while my mind will be concentrated on the forthcoming
results.

Anyone been buying or selling this week? Anyon else still using this BB?

This BB is extinct, bereft of life, it is no more. Well, probably a slight exaggeration. Everyone continues to wait for news - not a healthy position to be in. I will check on a couple of other BB sites whether anyone knows of a link between OXB and Cobra Bio - although I have not heard of such a link previously. Enjoy your holiday 1704.

Back again! Posted from another BB site: "Interesting to see Cobra Bio going nuts this morning after a big deal was signed to manufacture proteins. CBF manufacture for OXB. They are up 30% this morning."

I'm still reading this BB with interest. I have a very small holding so do not have too much to contribute on a daily basis but still watching...

Semi positive report in IC today

Great to hear from you guys (and you queen1)it gets a bit boring talking to
yourself. Appologies for not getting back to you earlier but I've been away
from my desk since mid-day (well I occasionally get some work done).

Pachandl-Well done! For finding the thread I was earlier talking about on the
advfn BB your make a good researcher if your not already. Not sure whether or
not it is true that CBF manufactures for OXB?

I'll have to pop into WH Smith on Sunday to see if I can read the article in
the IC that Fred1 mentioned.

Not the best of week's in the market for me (even though the Footsie has
surged beyond the 5000 level). In contrast to 2 weeks ago when I sold my
holding at 26p. The performance of the sp now makes less impressive reading:

OXB Price Change (Today -2.35%), 1 Day Change (-6.74%), 7 Days Change (-15.31%)
14 Days Change (-19.42%) 30 Days Change (18.75%).

They say a week's a long time in politics. They should should say OXB.

Have a good weekend and look foward to catching up with your posts on my
return. I hope my mood has improved (Grrrrrrr!).

1704 - to save you going to WHS

IC - poor sp performance after admitting that merger talks had been discontinued. Questions whether OXB can announce a Trovax licensing deal this year. Phase 11 data expected "later this year", Prosavin entering clinical trials, OXB "should generate plenty of newsflow in 2005. Also "some analysts believe that investors have not heard the last of the merger talks".

Overall comment - licensing deal for Trovax yet to materialise - shares look set to struggle until 2nd half of the year when trial data is reported. High enough.

Code Securities - neutral -2.3rds of sp based on Trovax.

Panmure - Buy - 2005 a big year for OXB - previous data from Trovax was positive - company also confident of pulling off at least one big deal this year.

Looks like we've reached buying level again.

I got some more this morning at less than 20p

Apple- I've also been adding to my holding this week. Looks like the winter sales have gone on into Feb this year.

Not worried about the dips in the sp this week as I can see the situation
being reversed by the end of this week and the sp heading northwards next week
as more investors pile into the stock ahead of the results.

I'm hoping to the sp at 35p by Mid-March 2005. However, time will tell.

1704 - I hope you are right as I intend to hold until mid-year, earliest.

Cobra CBF gave up dna after a relatively short period and moved into proteins and viruses.They seem to be the new babe on the block(plus MMG,of course).Unless there is another approach I think that OXB will drift a bit from now on.Held for six frustrating months,watching the day traders making lolly,because I bought at 20p.Finally made a nice bit because I sold at 27p . It was totally stressful. But then is'nt this whole business of the stk mkt a real worry at times.You are right to give yourself half a year,Pachandl.with your attitude,I would have been much happier last year...I wanted a quick buck.

Ethel - how ever long you hold the stock market is still worrying. At least the price seems to be consolidating so hopefully my patience will be eventually rewarded.

Pachandl-I think your strategy is a sensible one to hold at least until the
mid year. Personally I think that there will be opportunities to dip in and out
of this stock and make profits because of its volatility.

I've been following the market on Bloomberg TV today and was happy to
see that Merck and another large US Pharma (cannot recall the name) are
thinking of making a few acquisitions in the British pharma sector including
Bio-Techs. Apparently they have both got millions to invest. It would not
surprise me to see OXB being mentioned in the financial press as likely target
or takeover talks being announced within the next few weeks.

Pleased to see the sp stopping its falls today. I remain confident that there
will be a bounce back and my target price of 35p being achieved by mid
March 05. It will take more of a 'tree shake' by the MMs to get me out of this stock before the real fun begins.

Ethel-Pleased to hear that you eventually sold out at a profit after 6 months.
It can be stressful holding stocks like OXB but personally that is half the
attraction for me. Knowing that with luck and the right timing you can make
quick and sizeable profits in the stock market. Its feels great when it comes
right but very stressful if it does not go to plan. As well as carrying out my
own researchI I often rely on 'gut feeling' when I invest and remain confident
that OXB will deliver.

All the Best!

I presume this is the news that caused the jump in the share price just now, don't know why it hasn't come through as an RNS:

Oxford BioMedica said today that its collaborative partner Viragen Inc. reported that an antibody designed to treat malignant melanoma (anti-GD3 antibody) has been successfully detected in the blood of a founder transgenic rooster after the antibody was introduced using Oxford BioMedica's proprietary LentiVector(R) gene delivery system.
Viragen, in collaboration with the Roslin Institute, is developing avian transgenic biomanufacturing for the purpose of using chickens as bioreactors for the efficient and economical production of human pharmaceutical protein-based drugs in their eggs.
The latest achievement is the first in a series of steps designed to confirm that a humanised antibody can be produced in subsequent generations of chickens and demonstrate a fully intact structure capable of its intended therapeutic function.
-0-

ICV Edited News from Dow Jones
1357 GMT Feb 17 2005

RD- Thanks for the above information.

I was was flinking between the Bloomberg TV Channel and Kiss TV this afternoon when I saw the sp down by half a pence and then up by the same amount within a few minutes. I turned to my eldest son and said if that's what watching LL Cool Jay videos does to share prices I want more of it. Thank god for MTV Base and Kiss TV Channels this week they've certainly kept my blood pressure down with this stock.

The statement released today is positive news and bodes well for the other
results we are all eagerly awaiting (well I am anyway). I'm feeling more
bullish about this stock everyday 'ya get me'!

Financial Times 17/02/05 (Article: FTSE up on media strength'by Tony Tassell,
Philip Stafford and Chris Flood)

'More than 5.7 million shares were traded in Oxford Biomedica, the pharmaceutical group which ended takeover talks with an unnamed party earlier
this month. Rumours said it could shortly announce a deal to licence out further development of Trovax, its cancer vaccine. The shares were unchanged at
20p'.

I'm feeling more bullish about this stock everyday 'ya get me'!

1704 - FT - Beat me to posting it by 21mins - saw it earlier this afternoon but forgot to cut & paste.

is there any news about another merger with a big company?????????? has anyone one got news??????

Probable reason for the increase in sp:

BOSTON (AFX) -- Biotechnology and pharmaceutical issues scored modest gains Wednesday after a series of brokerage upgrades and gains in the broader market.

The Amex Biotechnology Index edged up 0.5 percent to 509.12 and the Amex Pharmaceutical Index added 0.2 percent to 314.79.

Human Genome Sciences advanced 1.3 percent to $11.15 after the genomics firm said it had completed enrollment for a Phase II clinical trial for its drug candidate HGS-ETR1, a treatment for advanced colorectal cancer.

Onyx Pharmaceuticals was the biggest winner among biotech issues, shooting up more than 9 percent at one point before resting at $30.08, up 7.4 percent. Analysts at Morgan Stanley upped their rating of the stock to 'overweight.'

Progenics Pharmaceuticals was upgraded by CIBC to 'outperform,' and the stock rose 4.6 percent to $22.04.

ImClone Systems shares inched up 1.8 percent to $42.57 after analysts at Morgan Stanley initiated coverage of the stock with an 'overweight' rating.

Gilead Sciences gained 1.9 percent to $33.77 in early afternoon on news that its HIV treatment Truvada had been approved by European regulators.

This story was supplied by MarketWatch. For further information see www.marketwatch.com.